Key result
Anthracycline exposure in patients with hematological malignancies led to significant ECG changes and the development of systolic left ventricular dysfunction in 12% of patients.
Why the study?
Anthracyclines cause cardiotoxic side effects related to cumulative dosages, and noninvasive methods to detect such cardiotoxicity need evaluation in patients with hematological malignancies.
Does anthracycline therapy induce detectable changes in ECG and echocardiography in patients with hematological malignancies?
Cross-Sectional (n=50)
No
Does anthracycline therapy induce detectable changes in ECG and echocardiography in patients with hematological malignancies?
Anthracycline therapy in hematological malignancies is associated with significant early ECG and echocardiographic changes, with LV systolic dysfunction occurring at a mean cumulative dose of approximately 250 mg/m2.
BACKGROUND: Anthracyclines are antibiotic antineoplastic drugs used in the treatment of various hematological and solid malignancies. They are well-known for their cardiotoxic side effects which are related to their cumulative dosages. Many investigations are used to detect such cardiotoxicity, the gold standard of which is the endomyocardial biopsy that has a limited use because it is an invasive procedure. The aims of this study were to explore the cardiotoxicity induced by anthracyclines in patients with hematological malignancies by using electrocardiography (ECG) and echocardiography and to determine relationship between the detected changes in ECG and echocardiography, with some demographic and clinical variables.PATIENTS AND METHODS: A cross-sectional study of fifty patients was recruited at Al-Imamein Al-Kadhemein Medical City from March 2014 to January 2015. ECG and echocardiography were done to the patients to study several parameters such as ejection fraction (EF), diastolic dysfunction, QRS voltage, QRS duration, and corrected QT (QTc) both at baseline and reassessment. Reassessment was done after completing induction for leukemia patients and at mid-term reassessment for lymphoma patients.RESULTS: ECG showed reduction in QRS voltage, increase in QRS duration, and increase in QTc, all of which showed statistical significance and may reflect the effect on the depolarization and repolarization on the myocardium. The echo study showed the development of systolic left ventricular (LV) dysfunction (EF <55%) in 12% of patients and a statistically significant reduction in the mean of EF of the study group. It also showed statistically significant development of new diastolic dysfunction. Statistically significant association between reduction of QRS voltage (>30% from baseline) with the development of LV dysfunction was also found.CONCLUSIONS: Significant changes in QRS voltage, QRS duration, QTc, as well as the occurrence of LV systolic dysfunction and diastolic dysfunction were noted. The mean cumulative dose at which LV systolic dysfunction occurred was about 250 mg/m2.
No takes yet. Share an insight, caveat, or question.
Saleh et al. (2019) conducted a cross-sectional in Hematological malignancies (n=50). Anthracyclines vs. Baseline was evaluated on Systolic left ventricular (LV) dysfunction (EF <55%). Anthracycline exposure in patients with hematological malignancies led to significant ECG changes and the development of systolic left ventricular dysfunction in 12% of patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: